Immune Suppression Clinical Trial
Official title:
The Immunomodulatory Effect of Bilateral Paravertebral Block and Total Intravenous Anesthesia in Spine Surgery.
Verified date | September 2020 |
Source | Mansoura University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
General anesthesia has an important effect on inflammatory cytokines. Inhalational agents as isoflurane and sevoflurane attenuate immune function expressed by neutrophil chemoattractant-1 as well as inflammatory enzyme and also they reduce inflammatory cascade. Total intravenous anesthesia (TIVA) based on using propofol suppresses the inflammatory response caused by surgery to a greater extent because Propofol affects the balance between pro-inflammatory and anti-inflammatory cytokines, increasing production of the anti-inflammatory cytokine IL-10 and at the same time reducing the increase of IL-6 during the perioperative period. It also alters expression of nitric oxide and inhibits neutrophil function. TIVA has many advantages such as; fewer side effects, earlier discharge, better patient satisfaction, faster recovery, less nausea and vomiting and reduced muscle relaxant requirements. Paravertebral block has an important role in the inflammatory and immune response. The paravertebral block can decrease perioperative inflammation and prevent immune suppression. Also, it can attenuate the cytokine response and reduce acute stress response caused by surgery. Decrease inflammation processes, improve surgery result, limit the duration of hospital stay, decrease post-operative fatigue and reduce postoperative complications.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 1, 2020 |
Est. primary completion date | August 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - patients scheduled for primary fixation of posterior lumbar spine surgery. - American Society of Anesthesia statuses I or II patients. - Single or double level lumbar spine fixation. - Fixed surgical team. Exclusion Criteria: 1. Patient refusal or uncooperative Patient. 2. History of allergy to any anesthetic agents will be used in the study. 3. Local sepsis. 4. Abnormal coagulation test results. 5. Usage of antiplatelet therapy. 6. Demyelinated neurological diseases as multiple sclerosis. 7. Mental retardation, psychotropic drug consumption. 8. Recurrent spine fixation. 9. Severe coronary or peripheral artery disease. 10. Severe cardiac disease, renal or hepatic failure. |
Country | Name | City | State |
---|---|---|---|
Egypt | Mansoura University Hospital | Mansourah | Dakahlia |
Lead Sponsor | Collaborator |
---|---|
Alaa Mazy Mazy |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum levels of interleukin 6 (IL-6). | picogram/milliliter using ELISA techniques. Measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative | |
Primary | Serum levels of interleukin 1ß (IL-1ß). | picogram/milliliter using ELISA techniques. Measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative. | |
Secondary | Total leukocyte count. | Number multiplied by 1000 /micro liter, measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative. | |
Secondary | Absolute neutrophil count. | Number multiplied by 1000 /micro liter, measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative. | |
Secondary | Neutrophil-Lymphocyte-Ratio (N/L ratio). | ratio. Measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative. | |
Secondary | Serum cortisol level. | Micro-gram per deciliter by immunoassays techniques. Measured Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | 24 hours postoperative. | |
Secondary | C-reactive protein serum level. | milligram per liter using ELISA techniques. | Basal: 30 minutes before starting anesthesia, 2 hours after starting surgery, 8 and 24 hours from the end of surgery postoperative. | |
Secondary | the time to the first analgesic request. | hours. | 24 hours postoperative. | |
Secondary | Total morphine consumption. | milligram. | 24 hours postoperative. | |
Secondary | The total amount of blood loss. | milliliter, estimated by weighing the swabs and blood suction loss. | Intraoperative; from the start of anesthesia to the end of surgery (minutes). | |
Secondary | The amount of allogenic blood transfusion. | Unites. | Intraoperative; from the start of anesthesia to the end of surgery (minutes). | |
Secondary | the duration of surgery. | Minutes, from the start of anesthesia to the extubation time. | intraoperative. | |
Secondary | The length of hospital stay. | Days, Starts from 0 hour postoperative time until patient discharge from the hospital. | 1-5 days postoperative. | |
Secondary | Mean arterial pressure | millimeter mercury | Basal 30 minutes preoperative, 5 minutes after intubation, 5 minutes after prone position, after 30, 60, 90, 120, 150, 180 min intraoperative. Postoperative, at 6, 12, 24 h after operation. | |
Secondary | Heart rate | Beats per minute. | Basal 30 minutes preoperative, 5 minutes after intubation, 5 minutes after prone position, after 30, 60, 90, 120, 150, 180 min intraoperative. Postoperative, at 6, 12, 24 h after operation. | |
Secondary | Numeric Pain Scale | A scale from 0 to 10, where 0= no pain, and 10= worst imaginable pain. The patient describe subjective pain feeling in a number from (0- 10). Measured basal 30 minutes before anesthesia, 30 min after para-vertebral block. postoperative at 6, 12, 24 hours. then after 1st, 2nd, 3rd months postoperative. | 24 hours postoperative. | |
Secondary | The European Quality of Life-5 Dimensions measures. | The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: 1, no problems, 2, slight problems, 3, moderate problems, 4, severe problems, and 5, extreme problems. by ticking a box. the final result is a 5 number code that represents the health state. | After 1st, 2nd, 3rd months postoperative. | |
Secondary | Basal Metabolic Rate | Calories. by the Mifflin - St Jeor equation equals = 10 × weight (kg) + 6.25 × height (cm) - 5 × age(y) + 5 | After 1st, 2nd, 3rd months postoperative. | |
Secondary | The rate of postoperative complications | the percent of the complications: thromboembolic events, surgical complications (Wound infection, bleeding, wound hematoma and neurological complication), postoperative fever, and nausea with vomiting. | Postoperative within 72 hours after surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT03445234 -
Blueberries, Bananas, Exercise Recovery
|
N/A | |
Active, not recruiting |
NCT04207177 -
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
|
Phase 4 | |
Completed |
NCT03572413 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.
|
Phase 4 | |
Recruiting |
NCT05635435 -
Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes
|
||
Completed |
NCT04315077 -
The Short Term Effects of Oceanix Supplementation on Recovery
|
N/A | |
Completed |
NCT03155984 -
Optimizing HBV Management During Anti-CD20 Antibodies
|
||
Recruiting |
NCT05739045 -
Nivolumab Combined With SOX Used in the Perioperative Treatment
|
Phase 2 | |
Completed |
NCT04885907 -
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05732779 -
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
|
N/A | |
Enrolling by invitation |
NCT04382508 -
Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.
|
||
Completed |
NCT04805216 -
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
|
||
Completed |
NCT05380778 -
Depth of Anesthesia and Proteomics
|
N/A | |
Completed |
NCT05407701 -
Cranberry Ingestion and Cycling Related Immunity and Inflammation
|
N/A | |
Completed |
NCT03937323 -
Immun Status at Pancreatitis Patients
|
||
Completed |
NCT05907135 -
Beet Supplementation, Exercise, Inflammation
|
N/A | |
Completed |
NCT05409092 -
Astaxanthin, Exercise Inflammation, Skin Health
|
N/A | |
Not yet recruiting |
NCT05591924 -
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
|
||
Recruiting |
NCT04526977 -
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).
|
||
Active, not recruiting |
NCT04345978 -
Effects of Fasting Strategies on Postoperative Recovery and Long-term Prognosis in Patients With Colorectal Cancer
|
N/A |